S.Biomedics Past Earnings Performance

Past criteria checks 0/6

S.Biomedics has been growing earnings at an average annual rate of 6.4%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 21.9% per year.

Key information

6.4%

Earnings growth rate

21.1%

EPS growth rate

Biotechs Industry Growth	11.7%
Revenue growth rate	21.9%
Return on equity	-17.5%
Net Margin	-29.7%
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why S.Biomedics (KOSDAQ:304360) Can Afford Some Debt

Jul 19

Revenue & Expenses Breakdown

How S.Biomedics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A304360 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	13,023	-3,862	5,680	6,196
30 Jun 24	11,901	-4,221	6,028	5,895
31 Mar 24	12,698	-7,357	5,833	6,100
31 Dec 23	13,108	-7,524	5,590	6,508
30 Sep 23	12,549	-10,072	5,204	6,613
30 Jun 23	13,790	-9,583	3,752	7,426
31 Mar 23	12,825	-6,987	4,408	6,039
31 Dec 22	12,113	-6,327	4,068	5,489
30 Sep 22	10,551	-6,669	3,940	5,201
30 Jun 22	8,631	-6,502	4,563	4,227
31 Mar 22	8,173	-5,723	3,325	5,199
31 Dec 21	8,868	-5,667	3,170	5,525
30 Sep 21	9,393	-5,628	3,060	5,633
30 Jun 21	8,844	-6,141	3,464	5,422
31 Mar 21	6,984	-7,468	3,653	5,739
31 Dec 20	5,319	-7,747	3,813	5,559
30 Sep 20	4,688	-8,029	3,536	6,151
30 Jun 20	5,112	-8,328	3,890	6,380
31 Mar 20	5,632	-8,108	3,881	6,175
31 Dec 19	5,014	-8,098	3,854	5,927
30 Sep 19	4,174	-10,265	4,084	4,772
30 Jun 19	3,258	-9,357	3,443	3,947
31 Mar 19	2,823	-10,778	3,200	3,721
31 Dec 18	3,160	-10,200	3,076	3,189
31 Dec 17	7,633	-5,250	3,559	2,233

Quality Earnings: A304360 is currently unprofitable.

Growing Profit Margin: A304360 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A304360 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.4% per year.

Accelerating Growth: Unable to compare A304360's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A304360 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A304360 has a negative Return on Equity (-17.47%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 07:23
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

S.Biomedics Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mihwa Seo	Mirae Asset Securities Co., Ltd.